Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, June 6, 2014, 96 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,133.00 to $126,311,991.43.

Highlighted Stocks Traded by Insiders:

UDR (UDR) - FREE Research Report

Toomey Thomas W, who is Chief Executive Officer at UDR, sold 15,000 shares at $27.90 on June 6, 2014. Following this transaction, the Chief Executive Officer owned 1.2 million shares meaning that the stake was reduced by 1.26% with the 15,000-share transaction.

The shares most recently traded at $27.84, down $0.06, or 0.22% since the insider transaction. Historical insider transactions for UDR go as follows:

  • 4-Week # shares sold: 21,000
  • 12-Week # shares sold: 26,800
  • 24-Week # shares sold: 26,800

The average volume for UDR has been 1.5 million shares per day over the past 30 days. UDR has a market cap of $7.1 billion and is part of the financial sector and real estate industry. Shares are up 20% year-to-date as of the close of trading on Friday.

UDR, Inc. is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It owns, operates, acquires, renovates, develops, redevelops, and manages multifamily apartment communities. The stock currently has a dividend yield of 3.68%. The company has a P/E ratio of 403.4. Currently, there are 3 analysts who rate UDR a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UDR - FREE

TheStreet Quant Ratings rates UDR as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, revenue growth, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full UDR Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mednax (MD) - FREE Research Report

Wagner Karl B, who is Pres, American Anesthesiology at Mednax, sold 44,596 shares at $58.53 on June 6, 2014. Following this transaction, the Pres, American Anesthesiology owned 130,195 shares meaning that the stake was reduced by 25.51% with the 44,596-share transaction.

Hawk William C, who is COO American Anesthesiology at Mednax, sold 6,911 shares at $57.66 on June 6, 2014. Following this transaction, the COO American Anesthesiology owned 15,022 shares meaning that the stake was reduced by 31.51% with the 6,911-share transaction.

The shares most recently traded at $58.76, up $1.10, or 1.87% since the insider transaction. Historical insider transactions for Mednax go as follows:

  • 4-Week # shares sold: 8,858
  • 12-Week # shares sold: 8,858
  • 24-Week # shares sold: 21,058

The average volume for Mednax has been 573,500 shares per day over the past 30 days. Mednax has a market cap of $5.8 billion and is part of the health care sector and health services industry. Shares are up 9.84% year-to-date as of the close of trading on Friday.

MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, and other pediatric subspecialties care physician services in the United States and Puerto Rico. The company has a P/E ratio of 20.4. Currently, there are 8 analysts who rate Mednax a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MD - FREE

TheStreet Quant Ratings rates Mednax as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Mednax Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sanderson Farms (SAFM) - FREE Research Report

Mooney Dianne, who is Director at Sanderson Farms, sold 6,010 shares at $97.37 on June 6, 2014. Following this transaction, the Director owned 8,944 shares meaning that the stake was reduced by 40.19% with the 6,010-share transaction.

The shares most recently traded at $94.44, down $2.93, or 3.11% since the insider transaction. Historical insider transactions for Sanderson Farms go as follows:

  • 4-Week # shares sold: 1,475
  • 12-Week # shares sold: 3,475
  • 24-Week # shares sold: 8,630

The average volume for Sanderson Farms has been 297,700 shares per day over the past 30 days. Sanderson Farms has a market cap of $2.2 billion and is part of the consumer goods sector and food & beverage industry. Shares are up 33.43% year-to-date as of the close of trading on Friday.

Sanderson Farms, Inc., an integrated poultry processing company, produces, processes, markets, and distributes fresh, frozen, and prepared chicken products in the United States. The stock currently has a dividend yield of 0.82%. The company has a P/E ratio of 11.6. Currently, there is 1 analyst who rates Sanderson Farms a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SAFM - FREE

TheStreet Quant Ratings rates Sanderson Farms as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Sanderson Farms Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null